The Numbers Don't Lie: What Not to Miss in J&J's Earnings

The video discusses the healthcare industry's focus on J&J's earnings amidst political developments. J&J is negotiating to acquire Actelion, leveraging its cash reserves. The company's pharmaceutical unit shows strong revenue growth, contributing significantly to sales. J&J is restructuring its medical devices division while facing competition for its drug Remicade. The stock has climbed steadily, but political factors, such as President Trump's stance on drug pricing, could impact future performance.

What impact does the Italian deal have on J&J's drug business?

What was President Trump's promise regarding the cost of medicines?